Comparative Pharmacology
Head-to-head clinical analysis: OPTOMYCIN versus POLYTRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTOMYCIN versus POLYTRIM.
OPTOMYCIN vs POLYTRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
Polymyxin B sulfate binds to the lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, disrupting membrane integrity and causing cell death. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA synthesis.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
1 drop in the affected eye(s) every 4 hours for 7-10 days.
None Documented
None Documented
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Terminal elimination half-life of polymyxin B is 4.5-6 hours; for trimethoprim it is 8-10 hours. In renal impairment, half-life of both components is prolonged.
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Renal excretion accounts for approximately 40% of the dose as unchanged polymyxin B and 60% as unchanged trimethoprim. Biliary/fecal elimination is minimal (<5% for each component).
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic